232 related articles for article (PubMed ID: 34545083)
1. Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B.
Deng MY; Sturm D; Pfaff E; Sill M; Stichel D; Balasubramanian GP; Tippelt S; Kramm C; Donson AM; Green AL; Jones C; Schittenhelm J; Ebinger M; Schuhmann MU; Jones BC; van Tilburg CM; Wittmann A; Golanov A; Ryzhova M; Ecker J; Milde T; Witt O; Sahm F; Reuss D; Sumerauer D; Zamecnik J; Korshunov A; von Deimling A; Pfister SM; Jones DTW
Nat Commun; 2021 Sep; 12(1):5530. PubMed ID: 34545083
[TBL] [Abstract][Full Text] [Related]
2. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas.
Barrow J; Adamowicz-Brice M; Cartmill M; MacArthur D; Lowe J; Robson K; Brundler MA; Walker DA; Coyle B; Grundy R
Neuro Oncol; 2011 Feb; 13(2):212-22. PubMed ID: 21138945
[TBL] [Abstract][Full Text] [Related]
3. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma.
Ghasimi S; Wibom C; Dahlin AM; Brännström T; Golovleva I; Andersson U; Melin B
J Neurooncol; 2016 May; 127(3):483-92. PubMed ID: 26839018
[TBL] [Abstract][Full Text] [Related]
4. The genetic landscape of gliomas arising after therapeutic radiation.
López GY; Van Ziffle J; Onodera C; Grenert JP; Yeh I; Bastian BC; Clarke J; Oberheim Bush NA; Taylor J; Chang S; Butowski N; Banerjee A; Mueller S; Kline C; Torkildson J; Samuel D; Siongco A; Raffel C; Gupta N; Kunwar S; Mummaneni P; Aghi M; Theodosopoulos P; Berger M; Phillips JJ; Pekmezci M; Tihan T; Bollen AW; Perry A; Solomon DA
Acta Neuropathol; 2019 Jan; 137(1):139-150. PubMed ID: 30196423
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive molecular characterization of pediatric radiation-induced high-grade glioma.
DeSisto J; Lucas JT; Xu K; Donson A; Lin T; Sanford B; Wu G; Tran QT; Hedges D; Hsu CY; Armstrong GT; Arnold M; Bhatia S; Flannery P; Lemma R; Hardie L; Schüller U; Venkataraman S; Hoffman LM; Dorris K; Mulcahy Levy JM; Hankinson TC; Handler M; Liu AK; Foreman N; Vibhakar R; Jones K; Allen S; Zhang J; Baker SJ; Merchant TE; Orr BA; Green AL
Nat Commun; 2021 Sep; 12(1):5531. PubMed ID: 34545084
[TBL] [Abstract][Full Text] [Related]
6. Better prognosis of patients with glioma expressing FGF2-dependent PDGFRA irrespective of morphological diagnosis.
Chen D; Persson A; Sun Y; Salford LG; Nord DG; Englund E; Jiang T; Fan X
PLoS One; 2013; 8(4):e61556. PubMed ID: 23630597
[TBL] [Abstract][Full Text] [Related]
7. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
[TBL] [Abstract][Full Text] [Related]
8. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
[TBL] [Abstract][Full Text] [Related]
9. Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas.
Alentorn A; Marie Y; Carpentier C; Boisselier B; Giry M; Labussière M; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Idbaih A
Neuro Oncol; 2012 Nov; 14(11):1393-403. PubMed ID: 23074200
[TBL] [Abstract][Full Text] [Related]
10. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
11. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
12. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.
Paugh BS; Qu C; Jones C; Liu Z; Adamowicz-Brice M; Zhang J; Bax DA; Coyle B; Barrow J; Hargrave D; Lowe J; Gajjar A; Zhao W; Broniscer A; Ellison DW; Grundy RG; Baker SJ
J Clin Oncol; 2010 Jun; 28(18):3061-8. PubMed ID: 20479398
[TBL] [Abstract][Full Text] [Related]
13. Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma.
Burford A; Little SE; Jury A; Popov S; Laxton R; Doey L; Al-Sarraj S; Jürgensmeier JM; Jones C
PLoS One; 2013; 8(8):e71777. PubMed ID: 23990986
[TBL] [Abstract][Full Text] [Related]
14. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas.
Martinho O; Longatto-Filho A; Lambros MB; Martins A; Pinheiro C; Silva A; Pardal F; Amorim J; Mackay A; Milanezi F; Tamber N; Fenwick K; Ashworth A; Reis-Filho JS; Lopes JM; Reis RM
Br J Cancer; 2009 Sep; 101(6):973-82. PubMed ID: 19707201
[TBL] [Abstract][Full Text] [Related]
15. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.
Koschmann C; Zamler D; MacKay A; Robinson D; Wu YM; Doherty R; Marini B; Tran D; Garton H; Muraszko K; Robertson P; Leonard M; Zhao L; Bixby D; Peterson L; Camelo-Piragua S; Jones C; Mody R; Lowenstein PR; Castro MG
Oncotarget; 2016 Oct; 7(40):65696-65706. PubMed ID: 27582545
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas.
Maragkou T; Reinhard S; Jungo P; Pasquier B; Neuenschwander M; Schucht P; Vassella E; Hewer E
Pathology; 2023 Jun; 55(4):466-477. PubMed ID: 37032198
[TBL] [Abstract][Full Text] [Related]
17. Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas.
Lazow MA; Hoffman L; Schafer A; Osorio DS; Boué DR; Rush S; Wright E; Lane A; DeWire-Schottmiller MD; Smolarek T; Sipple J; Taggert H; Reuss J; Salloum R; Hummel TR; de Blank P; Pillay-Smiley N; Sutton ME; Asher A; Stevenson CB; Drissi R; Finlay JL; Fouladi M; Fuller C
Acta Neuropathol Commun; 2020 Nov; 8(1):182. PubMed ID: 33153497
[TBL] [Abstract][Full Text] [Related]
18. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
19. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.
Puputti M; Tynninen O; Sihto H; Blom T; Mäenpää H; Isola J; Paetau A; Joensuu H; Nupponen NN
Mol Cancer Res; 2006 Dec; 4(12):927-34. PubMed ID: 17189383
[TBL] [Abstract][Full Text] [Related]
20. A glioma classification scheme based on coexpression modules of EGFR and PDGFRA.
Sun Y; Zhang W; Chen D; Lv Y; Zheng J; Lilljebjörn H; Ran L; Bao Z; Soneson C; Sjögren HO; Salford LG; Ji J; French PJ; Fioretos T; Jiang T; Fan X
Proc Natl Acad Sci U S A; 2014 Mar; 111(9):3538-43. PubMed ID: 24550449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
